Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Compass Therapeutics, Inc. CMPX
$3.21
-$0.09 (-2.73%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
430123800.00000000
-
week52high
5.65
-
week52low
1.36
-
Revenue
0
-
P/E TTM
-12
-
Beta
0.38747800
-
EPS
-0.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 04:00
Описание компании
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 05 мая 2022 г. |
| Ladenburg Thalmann | Buy | 15 мар 2022 г. | |
| B. Riley Securities | Buy | 19 янв 2022 г. | |
| Raymond James | Outperform | 22 дек 2021 г. | |
| SVB Leerink | Outperform | 20 дек 2021 г. | |
| Raymond James | Outperform | Outperform | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 ноя 2022 г. |
| EF Hutton | Buy | 16 дек 2022 г. | |
| Jefferies | Buy | 31 янв 2023 г. | |
| Stifel | Buy | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Schuetz Thomas J. | A | 5471873 | 20000 | 31 янв 2023 г. |
| Schuetz Thomas J. | A | 5451873 | 20000 | 24 янв 2023 г. |
| Bisker-Leib Vered | D | 1060414 | 2 | 25 ноя 2022 г. |
| Bisker-Leib Vered | D | 1060416 | 9569 | 23 ноя 2022 г. |
| Bisker-Leib Vered | D | 1069985 | 14929 | 22 ноя 2022 г. |
| Bisker-Leib Vered | D | 1084914 | 16035 | 21 ноя 2022 г. |
| Bisker-Leib Vered | D | 1107175 | 6226 | 18 ноя 2022 г. |
| ORBIMED ADVISORS LLC | A | 15219994 | 402000 | 08 ноя 2022 г. |
| GORDON CARL L | A | 15219994 | 402000 | 08 ноя 2022 г. |
| Schuetz Thomas J. | A | 5431873 | 10000 | 28 сент 2022 г. |
Новостная лента
Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
GlobeNewsWire
22 ноя 2022 г. в 08:00
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022.
Compass Therapeutics to Present at Upcoming Investment Conferences
GlobeNewsWire
08 ноя 2022 г. в 08:00
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022.
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
GlobeNewsWire
09 сент 2022 г. в 08:00
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place in New York City September 12 – 14, 2022.